NCT01131559View on ClinicalTrials.gov

Adjunctive Lisdexamfetamine (LDX) in Bipolar Depression

PHASE3TerminatedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

February 28, 2014

Study Completion Date

February 28, 2014

Conditions
BipolarDepression
Interventions
DRUG

Lisdexamfetamine

Oral; 20-70mg/day

DRUG

Placebo control

Oral; 20-70mg/day

Trial Locations (1)

45040

Lindner Center of HOPE, Mason

Sponsors

Collaborators (1)

Shire
All Listed Sponsors
collaborator

Shire

INDUSTRY

collaborator

University of Cincinnati

OTHER

lead

Lindner Center of HOPE

OTHER